Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an antifungal drug that is more
After the 2022 annual report and extraordinary general meeting, Ekobot is ready for the partially underwritten rights issue, providing capital for delivery of orders received,
Mdundo’s H1 results (July – December 2022) showed continued high growth across all KPIs with 23.4 million active users, 500,000 music tracks on Mdundo’s own
Ekobot expects to sell 25 of its unique farming robots this year, sign a distribution agreement in the Danish market and get one pilot customer
Biosergen has received approval for the next step in its phase 1 study of its drug against deadly fungal infections, which has blockbuster potential. Not
Biosergen AB stands in front of near-term price triggers and has a solid capital base to continue the development of the pipeline. 1.5 million people
Lifecare is trading at NOK 2.5, the price of the recently completed private placement, and there is therefore no need for a public issue at
Lifecare has completed a private placement of NOK 45 million at a 26% discount to yesterday’s price, equivalent to NOK 2.5 and a theoretical price
With investment from agriculture-based Dutch venture fund Navus Venures, Ekobot has not only gained new capital – at the market rate – but also, and
Mdundo A/S has today published the Q1 report for 2022/2023, which has offered new cooperation agreements and growth in the number of active users in
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.